Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Leber's congenital amaurosis (LCA) is a group of inherited blinding diseases with onset during childhood. One form of the disease, LCA2, is caused by mutations in the retinal pigment epithelium-specific 65-kDa protein gene (RPE65). We investigated the safety of subretinal delivery of a recombinant adeno-associated virus (AAV) carrying RPE65 complementary DNA (cDNA) (ClinicalTrials.gov number, NCT00516477 [ClinicalTrials.gov]). Three patients with LCA2 had an acceptable local and systemic adverse-event profile after delivery of AAV2.hRPE65v2. Each patient had a modest improvement in measures of retinal function on subjective tests of visual acuity. In one patient, an asymptomatic macular hole developed, and although the occurrence was considered to be an adverse event, the patient had some return of retinal function. Although the follow-up was very short and normal vision was not achieved, this study provides the basis for further gene therapy studies in patients with LCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The main disadvantage of this approach is the surgery itself. Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.4,87,88”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [88]
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [40]
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [42]
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationIdiopathic Senile Macular Hole: Its Early Stages and Pathogenesis
Gass, J. D. M. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130683026 · Cited by 992
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Self-citationMutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationRpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Self-citationNatural Course of Retinitis Pigmentosa Over a Three-Year Interval
Berson, E. L., Sandberg, M. A., Rosner, B., Birch, D. G., & Hanson, A. H. (1985) · American Journal of Ophthalmology · doi:10.1016/0002-9394(85)90351-4 · Cited by 321
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Self-citation
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Aguirre GD, 1998, Mol Vis, 4, 23
- 10.1038/88327 · DOI
- Fosnaugh JS, 1992, Methods Find Exp Clin Pharmacol, 14, 545
Cited by
Items 401–500 of 1,031
Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease
Yang, Y., & Dunbar, H. (2021) · Ophthalmologica · doi:10.1159/000515148 · Cited by 96
Rocca, C. J., Ur, S. N., Harrison, F., & Cherqui, S. (2014) · Gene Therapy · doi:10.1038/gt.2014.35 · Cited by 93
Qiao, C., Zhang, W., Yuan, Z., Shin, J.-H., Li, J., Jayandharan, G. R., Zhong, L., Srivastava, A., Xiao, X., & Duan, D. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.003 · Cited by 85
Klein, M., & Birch, D. G. (2009) · Documenta Ophthalmologica · doi:10.1007/s10633-009-9204-7 · Cited by 85
Georgiadis, A., Duran, Y., Ribeiro, J., Abelleira-Hervas, L., Robbie, S. J., Sünkel-Laing, B., Fourali, S., Gonzalez-Cordero, A., Cristante, E., Michaelides, M., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.66 · Cited by 84
Ellis, B. L., Hirsch, M. L., Porter, S. N., Samulski, R. J., & Porteus, M. H. (2013) · Gene Therapy · doi:10.1038/gt.2011.211 · Cited by 84
Sheffield, V. C., & Stone, E. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1012354 · Cited by 92
Self-citationState-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.
Wang, D., & Gao, G. (2014) · PubMed · Cited by 127
Electrical Stimulation of the Retina to Produce Artificial Vision
Weiland, J. D., Walston, S. T., & Humayun, M. S. (2016) · Annual Review of Vision Science · doi:10.1146/annurev-vision-111815-114425 · Cited by 84
Subretinal Gene Therapy of Mice With Bardet-Biedl Syndrome Type 1
Seo, S., Mullins, R. F., Dumitrescu, A. V., Bhattarai, S., Gratie, D., Wang, K., Stone, E. M., Sheffield, V., & Drack, A. V. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11673 · Cited by 83
Self-citationZhang, T., Zhang, N., Baehr, W., & Fu, Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017127108 · Cited by 83
Cronin, T., Raffelsberger, W., Lee-Rivera, I., Jaillard, C., Niepon, M.-L., Kinzel, B., Clérin, E., Petrosian, A. M., Picaud, S. A., Poch, O., et al. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.2 · Cited by 93
Donsante, A., Yi, L., Zerfas, P. M., Brinster, L., Sullivan, P., Goldstein, D. S., Prohaska, J. R., Centeno, J. A., Rushing, E. J., & Kaler, S. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.143 · Cited by 85
Maeda, T., Cideciyan, A. V., Maeda, A., Golczak, M., Aleman, T. S., Jacobson, S. G., & Palczewski, K. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp163 · Cited by 83
“Examples include surgical trauma to the macula–fovea (19,21), the amount of retina that can be detached without post-operative complications, possible immune reactions to a persistent vector (44) and the safety of enrolling individuals with high baseline serum antibody levels to the adeno-associated viral vector.”
BackgroundGenetic characterization and disease mechanism of retinitis pigmentosa; current scenario
Ali, M. U., Rahman, M. S. U., Cao, J., & Yuan, P. (2017) · 3 Biotech · doi:10.1007/s13205-017-0878-3 · Cited by 96
“Modest level improvements were achieved in visual acuity (Bainbridge et al. 2008; Cideciyan et al. 2008; Maguire et al. 2008).”
BackgroundGene therapy for ocular diseases
Liu, M. M., Tuo, J., & Chan, C.-C. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.174912 · Cited by 82
“100 Maguire et al described significantly improved pupillary light reflexes and self-reported improvements in dim light vision.(99) No vector-mediated adverse events were observed, though one patient developed a full thickness macular hole, and functional improvements persisted 1.”
BackgroundGibbs, D., Cideciyan, A. V., Jacobson, S. G., & Williams, D. S. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3471 · Cited by 82
Soltanmohammadi, F., Gharehbaba, A. M., Zangi, A. R., Adibkia, K., & Javadzadeh, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117248 · Cited by 95
Komáromy, A. M., Rowlan, J. S., Corr, A. T. P., Reinstein, S. L., Boye, S. L., Cooper, A. E., Gonzalez, A., Levy, B., Wen, R., Hauswirth, W. W., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.50 · Cited by 82
“3 CNGB3−/− R CNTF No 0, 1b + qRT-PCR (1)”
Comparative Analysis of DNA Nanoparticles and AAVs for Ocular Gene Delivery
Han, Z., Conley, S. M., Makkia, R., Guo, J., Cooper, M. J., & Naash, M. I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052189 · Cited by 82
“Recombinant adeno-associated viruses (AAVs) have been highly successful for ocular gene therapy due to their safety and ability to drive long-term gene expression [1,2,3,4].”
BackgroundProspects for retinal gene replacement therapy
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2009) · Trends in Genetics · doi:10.1016/j.tig.2009.02.003 · Cited by 100
Dalkara, D., Byrne, L. C., Lee, T., Hoffmann, N., Schaffer, D. V., & Flannery, J. G. (2011) · Gene Therapy · doi:10.1038/gt.2011.163 · Cited by 94
Gene therapy in the Cornea: 2005–present
Mohan, R. R., Tovey, J. C. K., Sharma, A., & Tandon, A. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.09.001 · Cited by 85
“Using AAV2, RPE65 gene was delivered to the retina of patients with Leber’s congenital amaurosis and successfully restored vision (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Maguire et al., 2009; Simonelli et al., 2010).”
BackgroundMethodLukason, M., DuFresne, E., Rubin, H., Pechan, P., Li, Q., Kim, I., Kiss, S., Flaxel, C., Collins, M., Miller, J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.230 · Cited by 81
Maeda, T., Lee, M. J., Palczewska, G., Marsili, S., Tesar, P. J., Palczewski, K., Takahashi, M., & Maeda, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.518571 · Cited by 86
“RPE65 gene transfer therapy has been initiated for patients with RPE65 mutations, and preliminary results are encouraging (35, 36).”
ResultA Phenotype–Genotype Correlation Study of X-Linked Retinoschisis
Vincent, A., Robson, A. G., Neveu, M. M., Wright, G., Moore, A. T., Webster, A. R., & Holder, G. E. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.12.008 · Cited by 81
Docosahexaenoic acid attenuates microglial activation and delays early retinal degeneration
Ebert, S., Weigelt, K., Walczak, Y., Drobnik, W., Mauerer, R., Hume, D. A., Weber, B. H. F., & Langmann, T. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06286.x · Cited by 81
Crosson, S. M., Dib, P., Smith, J. K., & Zolotukhin, S. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.05.001 · Cited by 79
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort
Perocheau, D. P., Cunningham, S. C., Lee, J., Antinao Diaz, J., Waddington, S. N., Gilmour, K., Eaglestone, S., Lisowski, L., Thrasher, A. J., Alexander, I. E., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.098 · Cited by 81
Boye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79
Advances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
Two decades of clinical gene therapy--success is finally mounting.
Herzog, R. W., Cao, O., & Srivastava, A. (2010) · PubMed · Cited by 102
Zou, J., Luo, L., Shen, Z., Chiodo, V. A., Ambati, B. K., Hauswirth, W. W., & Yang, J. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6141 · Cited by 95
Kellner, U., Kellner, S., Weber, B. H. F., Fiebig, B. S., Weinitz, S., & Rüether, K. (2008) · Eye · doi:10.1038/eye.2008.280 · Cited by 83
Calcedo, R., Somanathan, S., Qin, Q., Betts, M. R., Rech, A. J., Vonderheide, R. H., Mueller, C., Flotte, T. R., & Wilson, J. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617726114 · Cited by 79
“Reactive T cells were analyzed functionally and phenotypically using previously described techniques (1).”
MethodBioengineering strategies for restoring vision
Cehajic-Kapetanovic, J., Singh, M. S., Zrenner, E., & MacLaren, R. E. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00836-4 · Cited by 79
Mouse γ-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Wang, Q., Zhuang, P., Huang, H., Li, L., Liu, L., Webber, H. C., Dalal, R., Siew, L., Fligor, C. M., Chang, K.-C., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0102-20.2020 · Cited by 77
“…of adeno-associated virus (AAV)-mediated gene replacement in treating inherited retinal disease (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008, 2009; Busskamp et al., 2010; Gorbatyuk et al., 2010; Mingozzi and High, 2011; Boye et al., 2013; Smalley, 2017) makes…”
BackgroundGene therapy for inherited retinal diseases
Nuzbrokh, Y., Ragi, S. D., & Tsang, S. H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4726 · Cited by 79
“Initial human clinical trials in patients with severe disease confirmed a favorable adverse effect (AE) profile with complications consistent with SR injection with efficacy was supported by preclinical studies (14,15).”
BackgroundPawlyk, B. S., Bulgakov, O. V., Liu, X., Xu, X., Adamian, M., Sun, X., Khani, S. C., Berson, E. L., Sandberg, M. A., & Li, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.218 · Cited by 79
“These clinical trials have yielded important prelimi-nary outcomes indicating that this approach could be effective in restoring some degree of visual function (Bainbridge et al. , 2008; Hauswirth et al. , 2008; Maguire et al. , 2008).”
Collin, R. W. J., van den Born, L. I., Klevering, B. J., de Castro-Miró, M., Littink, K. W., Arimadyo, K., Azam, M., Yazar, V., Zonneveld, M. N., Paun, C. C., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6185 · Cited by 79
Naturally occurring animal models with outer retina phenotypes
Baehr, W., & Frederick, J. M. (2009) · Vision Research · doi:10.1016/j.visres.2009.04.008 · Cited by 79
Martin, J., Frederick, A., Luo, Y., Jackson, R., Joubert, M., Sol, B., Poulin, F., Pastor, E., Armentano, D., Wadsworth, S., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.046 · Cited by 79
“…2012) in addition to promising results in trials for Leber’s congenital amaurosis (Bainbridge et al. , 2008; Cideciyan et al. , 2008, 2009a,b; Maguire et al. , 2008, 2009; Simonelli et al. , 2010) and hemophilia B (Nathwani et al. , 2011) has served to further validate the potential for…”
AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models
Vasireddy, V., Mills, J. A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A. D., Alexandrov, K., Zhou, S., Maguire, A. M., Chung, D. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061396 · Cited by 79
“In the present study, we generated a vector using components very similar to those of the vector that we used successfully in Phase I/II studies in a clinical trial for Leber Congenital Amaurosis due to RPE65 mutations (LCA-RPE65), an AAV vector with serotype 2 capsid [25,50,51,52].”
MethodSelf-citationFirst-in-Human robot-assisted subretinal drug delivery under local anesthesia
Cehajic-Kapetanovic, J., Xue, K., Edwards, T. L., Meenink, T. C., Beelen, M. J., Naus, G. J., de Smet, M. D., & MacLaren, R. E. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.11.011 · Cited by 78
Pawlyk, B. S., Bulgakov, O. V., Sun, X., Adamian, M., Shu, X., Smith, A. J., Berson, E. L., Ali, R. R., Khani, S., Wright, A. F., et al. (2016) · Gene Therapy · doi:10.1038/gt.2015.93 · Cited by 77
Heller, P., Birke, A., Huesmann, D., Weber, B., Fischer, K., Reske‐Kunz, A., Bros, M., & Barz, M. (2014) · Macromolecular Bioscience · doi:10.1002/mabi.201400167 · Cited by 78
Hsp104 Suppresses Polyglutamine-Induced Degeneration Post Onset in a Drosophila MJD/SCA3 Model
Cushman-Nick, M., Bonini, N. M., & Shorter, J. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003781 · Cited by 80
rAAV-Mediated Subcellular Targeting of Optogenetic Tools in Retinal Ganglion Cells In Vivo
Wu, C., Ivanova, E., Zhang, Y., & Pan, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066332 · Cited by 82
Highly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina
Boye, S. E., Alexander, J. J., Witherspoon, C. D., Boye, S. L., Peterson, J. J., Clark, M. E., Sandefer, K. J., Girkin, C. A., Hauswirth, W. W., & Gamlin, P. D. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.085 · Cited by 78
Gonzalez-Cordero, A., Goh, D., Kruczek, K., Naeem, A., Fernando, M., kleine Holthaus, S.-M., Takaaki, M., Blackford, S. J. I., Kloc, M., Agundez, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.027 · Cited by 77
Varela, M. D., de Guimarães, T. A. C., Georgiou, M., & Michaelides, M. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318483 · Cited by 90
Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis
Ferrari, S., Ponzin, D., Ashworth, J. L., Fahnehjelm, K. T., Summers, C. G., Harmatz, P., & Scarpa, M. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.179937 · Cited by 84
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.(4,87,88) The technique itself requires significant surgical experience.”
BackgroundHaurigot, V., Villacampa, P., Ribera, A., Bosch, A., Ramos, D., Ruberte, J., & Bosch, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041511 · Cited by 83
Scalabrino, M. L., Boye, S. L., Fransen, K. M. H., Noel, J. M., Dyka, F. M., Min, S. H., Ruan, Q., De Leeuw, C. N., Simpson, E. M., Gregg, R. G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv341 · Cited by 76
Chadderton, N., Palfi, A., Millington-Ward, S., Gobbo, O., Overlack, N., Carrigan, M., O'Reilly, M., Campbell, M., Ehrhardt, C., Wolfrum, U., et al. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.112 · Cited by 76
Koirala, A., Makkia, R. S., Conley, S. M., Cooper, M. J., & Naash, M. I. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt013 · Cited by 75
Therapeutic promise of engineered nonsense suppressor tRNAs
Porter, J. J., Heil, C. S., & Lueck, J. D. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1641 · Cited by 77
“This idea comes from results of several human gene replacement studies where no T-cell immunity to the target protein was identified (Brantly et al., 2009; Cideciyan, 2010; Hauswirth et al., 2008; Maguire et al., 2008; Mendell et al., 2009).”
ResultGenotype-Phenotype Correlation for Leber Congenital Amaurosis in Northern Pakistan
McKibbin, M., Ali, M., Mohamed, M. D., Booth, A. P., Bishop, F., Pal, B., Springell, K., Raashid, Y., Jafri, H., & Inglehearn, C. F. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.309 · Cited by 78
“2 (2-43) 6/60 to NPL Common (92) Common (77) CRB1 10 28.”
Vashist, S., Cushman-Nick, M., & Shorter, J. (2010) · Biochemistry and Cell Biology · doi:10.1139/o09-121 · Cited by 87
“Gene therapy has produced encouraging preclinical outcomes for a number of disorders (Bainbridge et al. 2008; Hacein-Bey-Abina et al. 2002; Maguire et al. 2008), yet technical and safety issues have restricted translation to the clinic.”
Treatment of Diabetes and Long-Term Survival After Insulin and Glucokinase Gene Therapy
Callejas, D., Mann, C. J., Ayuso, E., Lage, R., Grifoll, I., Roca, C., Andaluz, A., Fernández, R. R. D. G. I., Montané, J., MUÑOZ, S. A., et al. (2013) · Diabetes · doi:10.2337/db12-1113 · Cited by 99
“This was demonstrated by the work performed in gene transfer for hemophilia B (12,25–27) and Leber congenital amaurosis (13,28), in which results for dogs were fully predictive of the outcome in humans.”
BackgroundSelf-citationGene therapy for Stargardt disease associated with ABCA4 gene
Han, Z., Conley, S. M., & Naash, M. I. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_90 · Cited by 74
“In the past two decades, gene therapy for human ocular disorders has produced remarkable breakthroughs [12–14].”
BackgroundThe special case of gene therapy pricing
Brennan, T. A., & Wilson, J. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.3003 · Cited by 77
In Vivo Genome Editing as a Therapeutic Approach
Ho, B. X., Loh, S. J. H., Chan, W., & Soh, B.-S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092721 · Cited by 83
“…2016 [55] Alpha-1 antitrypsin (AAT) deficiency Mouse Song et al., 2018 [56] Cancer PD-L1+ Tumor xenograftmodel (in vivo); Human Rupp et al., 2017 [57] Castillo et al., 2016 [58] Leber’s congenital amaurosis (LCA) Human Bainbridge et al., 2008 [59] Maguire et al., 2008 [60] Ruan et al., 2017 [61]”
BackgroundHow genetic errors in GPCRs affect their function: Possible therapeutic strategies
Stoy, H., & Gurevich, V. V. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.02.005 · Cited by 83
Gene therapy in the second eye of RPE65-deficient dogs improves retinal function
Annear, M. J., Bartoe, J. T., Barker, S. E., Smith, A. J., Curran, P. G., Bainbridge, J. W., Ali, R. R., & Petersen-Jones, S. M. (2011) · Gene Therapy · doi:10.1038/gt.2010.111 · Cited by 74
Weleber, R. G., Michaelides, M., Trzupek, K. M., Stover, N. B., & Stone, E. M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6106 · Cited by 74
Self-citationAn experimental platform for systemic drug delivery to the retina
Campbell, M., Nguyen, A. T. H., Kiang, A.-S., Tam, L. C. S., Gobbo, O. L., Kerskens, C., Dhubhghaill, S. N., Humphries, M. M., Farrar, G.-J., Kenna, P. F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908561106 · Cited by 73
CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.003 · Cited by 74
Self-citationMussolino, C., Sanges, D., Marrocco, E., Bonetti, C., Di Vicino, U., Marigo, V., Auricchio, A., Meroni, G., & Surace, E. M. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201000119 · Cited by 74
“…degeneration [recently also in Rho / mice; (Chadderton et al, 2009)], as well as clinical trials (Bainbridge et al, 2008; Hauswirth et al, 2008; Maguire et al, 2008); and (iii) there is the possibility to incorporate two genes into the same vector (both the silencing and the replacement…”
BackgroundSelf-citationMihelec, M., Pearson, R. A., Robbie, S. J., Buch, P. K., Azam, S. A., Bainbridge, J. W. B., Smith, A. J., & Ali, R. R. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.069 · Cited by 72
“This suggests that LCA1 is a fairly stationary condition with minor structural deterioration with age, and that there might be a relatively long opportunity for treatment compared, for instance, with patients of a similar age with RPE65 mutations whose retinal structures are compromised to a greater extent (Pasadhika…”
BackgroundHickey, D. G., Edwards, T. L., Barnard, A. R., Singh, M. S., de Silva, S. R., McClements, M. E., Flannery, J. G., Hankins, M. W., & MacLaren, R. E. (2017) · Gene Therapy · doi:10.1038/gt.2017.85 · Cited by 72
Cereso, N., Pequignot, M. O., Robert, L., Becker, F., De Luca, V., Nabholz, N., Rigau, V., De Vos, J., Hamel, C. P., & Kalatzis, V. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.11 · Cited by 72
AAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations
Pacouret, S., Bouzelha, M., Shelke, R., Andres-Mateos, E., Xiao, R., Maurer, A., Mevel, M., Turunen, H., Barungi, T., Penaud-Budloo, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.001 · Cited by 69
A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders
Vrellaku, B., Hassan, I. S., Howitt, R., Webster, C. P., Harriss, E., McBlane, F., Betts, C., Schettini, J. L., Lion, M., Mindur, J. E., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.016 · Cited by 84
Leber Hereditary Optic Neuropathy Gene Therapy Clinical Trial Recruitment: Year 1
Lam, B. L. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.201 · Cited by 73
“Still, the Leber congenital amaurosis phase 1 clinical trial showed that partial return of visual function may occur even in blind eyes with long-standing and severe photoreceptor loss.(23,24) Perhaps insertion of the normal ND4 gene into the mitochondria of remaining ganglion cells may restore some level of visual fu…”
BackgroundJayandharan, G. R., Aslanidi, G., Martino, A. T., Jahn, S. C., Perrin, G. Q., Herzog, R. W., & Srivastava, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012753108 · Cited by 72
RetractedScholl, H. P. N., Moore, A. T., Koenekoop, R. K., Wen, Y., Fishman, G. A., van den Born, L. I., Bittner, A., Bowles, K., Fletcher, E. C., Collison, F. T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143846 · Cited by 71
Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A., Sahel, J., & Dalkara, D. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26031 · Cited by 71
“AAVs are currently the vectors of choice and have been used successfully in the treatment of hemophilia (Nathwani et al., 2011; Nathwani et al., 2014) and in retinal degeneration (Bainbridge et al., 2008; Cideciyan et al., 2008; Maguire et al., 2008).”
BackgroundAdeno-associated Virus: A Key to the Human Genome?
Henckaerts, E., & Linden, R. M. (2010) · Future Virology · doi:10.2217/fvl.10.48 · Cited by 71
“Three independent Phase I dose-escalation studies show that subretinal injection of AAV2 vectors encoding RPE65 cDNA is safe and, in some cases, leads to sustained improvement in objective and subjective measurements of vision [40–43].”
BackgroundVoretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence
Gao, J., Hussain, R. M., & Weng, C. Y. (2020) · Clinical ophthalmology · doi:10.2147/opth.s231804 · Cited by 86
Ocular Delivery of Compacted DNA-Nanoparticles Does Not Elicit Toxicity in the Mouse Retina
Ding, X.-Q., Quiambao, A. B., Fitzgerald, J. B., Cooper, M. J., Conley, S. M., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007410 · Cited by 71
“For example, restoration of retinal function by viral-mediated gene delivery was documented in canine (RPE652/2 dog) [3,4] and mouse models of Leber Congenital Amaurosis, in mouse models of retinitis pigmentosa (rd mice) [5], and in mouse models of complete achromatopsia (Gnat22/2 mice) [6].”
BackgroundAdvances in AAV Vector Development for Gene Therapy in the Retina
Day, T. P., Byrne, L. C., Schaffer, D. V., & Flannery, J. G. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_86 · Cited by 71
“AAV2, the best characterized AAV serotype, was used in seminal clinical trials for Leber’s congenital amaurosis type 2 (LCA2), an autosomal recessive retinal dystrophy caused by a mutation in RPE65, by three independent groups in 2008 [2, 10, 18].”
MethodMultifunctional nanocomplexes for gene transfer and gene therapy
Hart, S. L. (2010) · Cell Biology and Toxicology · doi:10.1007/s10565-009-9141-y · Cited by 75
“…disease type X1 (SCID-X1) patients in two separate studies using retroviral vectors (Cavazzana-Calvo et al. 2000; Gaspar et al. 2004) as well as three studies of retinal degeneration using adeno-associated viral (AAV) vectors (Cideciyan et al. 2008; Maguire et al. 2008; Bainbridge et al. 2008).”
BackgroundA review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium
Koirala, A., Conley, S. M., & Naash, M. I. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.002 · Cited by 71
Heat shock proteins in the retina: Focus on HSP70 and alpha crystallins in ganglion cell survival
Piri, N., Kwong, J. M. K., Gu, L., & Caprioli, J. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.03.001 · Cited by 82
“AAV-based gene therapy appears to be an attractive strategy for the treatment of different ocular diseases, including glaucoma, and has been evaluated in clinical trials in patients with Leber's congenital amaurosis and choroideremia (Hauswirth et al., 2008; Maguire et al., 2008; MacLaren et al., 2014).”
BackgroundGene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
Whittemore, K., Derevyanko, A., Martinez, P., Serrano, R., Pumarola, M., Bosch, F., & Blasco, M. A. (2019) · Aging · doi:10.18632/aging.101982 · Cited by 69
Pang, J., Boye, S. E., Lei, B., Boye, S. L., Everhart, D., Ryals, R., Umino, Y., Rohrer, B., Alexander, J., Li, J., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.29 · Cited by 70
The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes
Wang, J., Faust, S. M., & Rabinowitz, J. E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.017 · Cited by 75
“expressing the therapeutic RPE65 gene to patients affected with Leber congenital amaurosis [92–95].”
BackgroundSrivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 71
Ocular gene therapy: current progress and future prospects
Colella, P., Cotugno, G., & Auricchio, A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.003 · Cited by 78
“expression cassette, which contained either the RPEspecific RPE65 promoter [73] or the ubiquitous chicken b actin (CBA) promoter [ 74 ,75,77]; the AAV vector injection volumes; and the baseline conditions of the patients’ visual function.”
BackgroundInfluentialSelf-citationTseng, Y.-S., Gurda, B. L., Chipman, P., McKenna, R., Afione, S., Chiorini, J. A., Muzyczka, N., Olson, N. H., Baker, T. S., Kleinschmidt, J., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02710-14 · Cited by 70
A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration
Wu, Z., Hiriyanna, S., Qian, H., Mookherjee, S., Campos, M. M., Gao, C., Fariss, R., Sieving, P. A., Li, T., Colosi, P., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv134 · Cited by 69
Lu, Q., Ganjawala, T. H., Ivanova, E., Cheng, J. G., Troilo, D., & Pan, Z.-H. (2016) · Gene Therapy · doi:10.1038/gt.2016.42 · Cited by 70
Nonsyndromic Retinitis Pigmentosa Overview
Fahim, A. T., Daiger, S. P., & Weleber, R. G. (2017) · Europe PMC (PubMed Central) · Cited by 80
Emerging approaches for restoration of hearing and vision
Kleinlogel, S., Vogl, C., Jeschke, M., Neef, J., & Moser, T. (2020) · Physiological Reviews · doi:10.1152/physrev.00035.2019 · Cited by 91
Bairagi, R. D., Reon, R. R., Hasan, M. M., Sarker, S. K., Debnath, D., Rahman, M. T., Rahman, S., Islam, M. A., Siddique, M. A. T., Bokshi, B., et al. (2025) · Discover Nano · doi:10.1186/s11671-025-04234-6 · Cited by 94
“Polymeric nanoparticles can overcome these barriers by facilitating drug penetration and providing prolonged drug retention at the target site [317].”
Technical brief: subretinal injection and electroporation into adult mouse eyes.
Johnson, C. J., Berglin, L., Chrenek, M. A., Redmond, T. M., Boatright, J. H., & Nickerson, J. M. (2008) · PubMed Central · Cited by 69
Self-citation
Metadata
- Authors
- Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.-X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., & Bennett, J.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- University of Iowa (US)
- Veterans Health Administration (US)
- Children's Hospital of Pittsburgh (US)
- University of Oklahoma (US)
- National Eye Institute (US)
- ORCID
- Maguire, Albert M.
- Simonelli, Francesca
- Pierce, Eric A.
- Pugh, Edward N.
- Mingozzi, Federico
- Banfi, Sandro
- Testa, Francesco
- Surace, Enrico M.
- Rossi, Settimio
- Arruda, Valder R.
- Konkle, Barbara
- Stone, Edwin
- Sun, Junwei
- Hertle, Richard
- Ma, Jian-xing
- Redmond, T. Michael
- Zhu, Xiaosong
- Shindler, Kenneth S.
- Maguire, Maureen G.
- Wright, J. Fraser
- Volpe, Nicholas J.
- Auricchio, Alberto
- High, Katherine A.
- Bennett, Jean
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2240-2248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2829748
- OpenAlex
- W2137222303
- Cited by
- 2,145
- References
- 27
- Citations by year
- 2026: 38 · 2025: 68 · 2024: 51 · 2023: 66 · 2022: 79 · 2021: 110 · 2020: 96 · 2019: 98 · 2018: 118 · 2017: 144 · 2016: 124 · 2015: 172 · 2014: 152 · 2013: 155 · 2012: 158
- FWCI
- 70.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Eye Institute (EY10820, R01EY010820)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, adeno-associated virus vectors, retinal pigment epithelium, macular hole, visual acuity, retinal function, adverse events, inherited retinal degeneration
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Promoter Regions, Genetic, Reflex, Pupillary, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.